Turn Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$8.4MTTM through 30 Jun 2026
Free Cash Flow -$4.3MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-49.8%ROA
Balance Sheet Health
Debt / Equity0.98x
Current Ratio2.23x
Net Debt-$5.3Mnet cash position
Cash & Equivalents$9.9M
Quality Metrics
Altman Z-Score13.47
Piotroski F-Score1 / 9
Multi-Year Trend
Diluted EPS-$0.29TTMFY2025: $-0.12
Dividend
No dividend
Capital Allocation
R&D Spend$778.1K
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.